bemcentinib

Bemcentinib is an orally available, selective small molecule inhibitor of the AXL receptor tyrosine kinase (also known as UFO), developed primarily for its antineoplastic activity. By binding to the intracellular catalytic kinase domain of AXL, it blocks AXL-mediated signal transduction pathways, inhibiting epithelial-mesenchymal transition (EMT), tumor cell proliferation, migration, and enhancing chemosensitivity. Overexpression of AXL is associated with drug resistance and poor prognosis in various cancers. Bemcentinib has been investigated in multiple clinical trials for solid tumors and hematological malignancies—including non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), triple-negative breast cancer (TNBC), melanoma, myelodysplastic syndromes (MDS), malignant mesothelioma, glioblastoma, pancreatic cancer—and has also been studied as a potential antiviral agent against COVID-19.

Brand names

Tinosorb SEscalol SParsol Shield

Other names

bemcentinib